A Randomised, Double-blind, Parallel-group, Explorative Study of the Safety, Tolerability, and Pharmacokinetics of Daily Dosing Compared to Weekly Dosing of Zicronapine in Patients With Schizophrenia

Trial Profile

A Randomised, Double-blind, Parallel-group, Explorative Study of the Safety, Tolerability, and Pharmacokinetics of Daily Dosing Compared to Weekly Dosing of Zicronapine in Patients With Schizophrenia

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Mar 2016

At a glance

  • Drugs Zicronapine (Primary)
  • Indications Schizophrenia
  • Focus Adverse reactions
  • Sponsors Lundbeck A/S
  • Most Recent Events

    • 28 Feb 2012 Actual end date (Feb 2012) added as reported by ClinicalTrials.gov.
    • 28 Feb 2012 Actual patient number is 42 according to ClinicalTrials.gov.
    • 28 Feb 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top